IceCure begins eliminating cancer by freezing in Israel

ProSense Photo: PR
ProSense Photo: PR

In the coming month, Elisha Hospital in Haifa will start implementing IceCure's treatments for eliminating benign breast tumors and cancerous kidney tumors.

In the coming month, Elisha Hospital in Haifa will start implementing IceCure Medical Ltd's (TASE: ICCM) treatments for eliminating benign breast tumors and cancerous kidney tumors - by freezing and with no surgery

IceCure is an Israeli medical device company that has developed technology for eliminating benign and cancerous tumors in the breast and other parts of the body by freezing the tumor during treatment in a clinic and without surgery, uses the ProSense system, developed at the Elisha Private Hospital in Haifa. Commercial distribution in Israel will be carried out by Duke Medical Solutions.

Treatment of the breast will be performed by Dr. Rafi Klein - Head of Breast Surgery at Elisha Hospital and Rambam Medical Center - in his clinic at Elisha Hospital for patients with fibroadenoma type benign tumors of up to 5 centimeters in diameter as an alternative to surgery. In the future, the hospital also plans performing these treatments on patients with cancerous breast tumors. Treatment of the kidneys will be performed by Prof. Ofer Nativ, Head of the Urological Department at the Bnai Zion Medical Center and Elisha Hospital and by Dr. Robert Sachner, Head of Interventional Radiology at the Bnai Zion Medical Center and Elisha Hospital.

Treatment using ProSense is based on a system that streams liquid nitrogen is a closed circuit and then freezes with a unique needle developed by IceCure, benign and malignant tumors while protecting the healthy tissues surrounding the tumor and eradicating the entire tumor. The treatment of breast tumors uses a minimally invasive approach that allows swift recovery with no scars. The treatment lasts about 20-40 minutes in a medical clinic, without surgery, hospitalization or stitches and without changing the shape or size of the breast. Consequently after treatment the patient is able to return quickly to daily activities and follow-up of the lesion is similar to follow-up after surgical removal.

IceCure Medical CEO Eyal Shamir said, "We are delighted with the start of commercial treatment in Israel of breast and kidney tumors, which represents acknowledgement by the medical establishment in Israel that our technology is an alternative that makes unnecessary the need for surgery and cutting open the breast. Treatment in Israel joins the successful commercial treatment that has already been performed with our technology in Japan, the US, Hong Kong and Europe for various indications including breast, lung, bone, kidney and liver cancers. We recently reported the first successful results in a large trial for breast cancer, which reflects a very low percentage of recurrence of cancer after treatment with ProSense™ in which out of 146 patients, only one showed recurrence of cancer and about 76% of patients returned to full daily activities about 48 hours after the treatment was completed, and 95% of the patients and the doctors reported satisfaction with the cosmetic results."

Elisha Hospital Director General Dr. Shlomo Israelit said, "Elisha Hospital is proud to be the first hospital leading medical progress in the field of alternative treatment to surgery for benign breast tumors and cancerous tumors in the kidneys. Freezing technology is the correct alternative for the improvement of the patients' experience and of course the cosmetic results. In the future, we will also enter the field of treating cancerous breast tumors. I am proud of the cooperation with the all Israeli biotech company that has developed this successful product and chose Elisha Hospital as the first hospital to use this technology. Elisha Hospital welcomes IceCure's leadership of a revolution in the field and wishes us success on our common path towards good, proper and progressive medicine for all patients."

Published by Globes [online], Israel business news - - on August 15, 2018

© Copyright of Globes Publisher Itonut (1983) Ltd. 2018

ProSense Photo: PR
ProSense Photo: PR
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018